

## ASX ANNOUNCEMENT

### Appointment of Dr. Peter B. Corr as Director

**23rd May 2017 - Brisbane, Australia – Analytica Ltd (ASX: ALT)** is pleased to announce the appointment of Dr. Peter B. Corr to the Board of Analytica Ltd.

Dr. Corr has been invited to join the Board due to his extensive experience in the discovery and development of medicines in multiple indications, as well as the sale of assets to major multinational corporations.

Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology at Washington University in St. Louis. His research has been published in more than 160 scientific manuscripts. After 18 years, Dr. Corr left Washington University to become Senior Vice President for Discovery Research at Monsanto/Searle. Subsequently, Dr. Corr became President of Worldwide Research and Development at Warner Lambert/Parke Davis until the company was acquired by Pfizer. At Pfizer, Dr. Corr was initially President of Worldwide Development, and subsequently Senior Vice President, Science and Technology. He also headed Pfizer's worldwide pharmaceutical research and development.

Dr. Corr retired from Pfizer Inc in December 2006 and subsequently Co-Founded and is the Managing General Partner of Auen Therapeutics, a private equity firm pursuing an innovative life science investment strategy where products are acquired, developed and then sold to multinational pharmaceutical firms.

Dr. Corr, who received his doctorate from Georgetown University School of Medicine, spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis. Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology.

Dr. Corr is the recipient of numerous awards, including membership in the Alpha Omega Alpha National Medical Honorary Society, an Established Investigator Award from the American Heart Association, and a Research Career Development Award from the National Institutes of Health. He received the Washington University School of Medicine Teacher of the Year Award on several occasions and, in 1990, the Washington University Distinguished Faculty Award. In 2004, Dr. Corr was named a William Pitt Fellow at Pembroke College, Cambridge University, Cambridge, U.K.

Dr. Corr was Chairman of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); Chairman of the PhRMA Foundation Board of Directors; and Chairman of the Hever Group, representing Chief Scientific Officers (CSO's) across the European and U.S. based pharmaceutical industry.

He is a past Governor of the New York Academy of Sciences (and past Chairman of the Board of Governors) and a member of the Board of Regents of Georgetown University, and a past Member. He is currently Chairman of the Board of ADC Therapeutics, SA in Lausanne, Switzerland and a Board Member of Imvax, Inc. based in Philadelphia.



Dr. Corr is also the majority owner and director of INOV8, LLC in the US Virgin Islands which has a 12.58% shareholding in Analytica Ltd.

The Board has also offered to Dr Corr, subject to shareholder approval at the next shareholders meeting a grant of 10 million options with an exercise price of \$0.013 and a 5 year life.

Dr Michael Monsour

Chairman

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



### About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from [pericoach.com](http://pericoach.com) in Australia, New Zealand, UK and Ireland, and the USA.

